Danaher Corporation shares fell in pre-market trading after the company reported second-quarter results that beat expectations but offered a cautious growth outlook.
Danaher Corporation shares dropped between 9% and 14.57% in pre-market trading on Tuesday following the release of second-quarter financial results. While the life sciences and diagnostics company exceeded Wall Street estimates, investors reacted to a more conservative near-term growth forecast. The company reported adjusted earnings per share of $1.94, surpassing the analyst consensus of $1.83 to $1.84. Revenue rose 5.5% year over year to approximately $6.3 billion, beating the expected $6.1 billion. Rainer Blair, President and Chief Executive Officer, noted that the Life Sciences businesses delivered their strongest quarter in several years. Despite the earnings beat and a raised full-year 2026 adjusted earnings guidance of $8.45 to $8.60, the market responded to a lowered core revenue growth forecast. The company adjusted its 2026 core revenue growth outlook to 3% to 4% and adopted a more cautious stance on the Bioprocessing business. Management expects core revenue growth of 2% to 3% for the third quarter.